This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.


Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


Sandbox 45673

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 30: Line 30:
<references/>
<references/>
Allen, Helen. (2015, March). "Finasteride for prostate gland enlargement. Information. Patient.
Allen, Helen. (2015, March). "Finasteride for prostate gland enlargement. Information. Patient.
 +
 +
Bull, Herbert G.*Garcia-Calvo,Margarita Andersson,Stefan†, Baginsky, Walter F.
 +
Chan,H. Karen,Ellsworth,‡ Dina E., Miller,§ Randall R., Stearns,Ralph A.,
 +
Bakshi,Raman K.,Rasmusson, Gary H.,Tolman,Richard L., Myers,Robert W.,
 +
Kozarich,John W.,Harris,Georgianna S. (1995, August 6) Mechanism-Based Inhibition of Human Steroid 5R-Reductase by Finasteride: Enzyme-Catalyzed Formation of NADP-Dihydrofinasteride, a Potent Bisubstrate Analog Inhibitor. http://pubs.acs.org/doi/pdf/10.1021/ja953069t
Leyden, J., Dunlap, F., & Miller, B., et el. (1999, June). Finasteride in the treatment of men with frontal male pattern hair loss.
Leyden, J., Dunlap, F., & Miller, B., et el. (1999, June). Finasteride in the treatment of men with frontal male pattern hair loss.
Olsen, E. A., Hordinsky, M., & Whiting, D., et al. (2006, December). The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: Results of a randomized placebo-controlled study of dutasteride versus finasteride.
Olsen, E. A., Hordinsky, M., & Whiting, D., et al. (2006, December). The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: Results of a randomized placebo-controlled study of dutasteride versus finasteride.
 +
 +
Schieck, Cynthia L.(1998, August) "Finasteride (Propecia ®)". http://www.chm.bris.ac.uk/motm/finasteride/Finasteride%20(Propecia)%20-%20Feature%20Molecule.htm

Revision as of 01:07, 17 November 2016

N-(1,1-dimethylethyl)-3-oxo-(5α,17β)-4-azaandrost-1-ene-17-carboxamide

N-(1,1-dimethylethyl)-3-oxo- (5α,17β)-4-azaandrost-1-ene-17-carboxamide (PDB code 3g1r)

Drag the structure with the mouse to rotate

References

Allen, Helen. (2015, March). "Finasteride for prostate gland enlargement. Information. Patient.

Bull, Herbert G.*Garcia-Calvo,Margarita Andersson,Stefan†, Baginsky, Walter F.

Chan,H. Karen,Ellsworth,‡ Dina E.,  Miller,§ Randall R.,  Stearns,Ralph A.,
Bakshi,Raman K.,Rasmusson, Gary H.,Tolman,Richard L., Myers,Robert W.,
Kozarich,John W.,Harris,Georgianna S. (1995, August 6) Mechanism-Based Inhibition of Human Steroid 5R-Reductase by Finasteride: Enzyme-Catalyzed Formation of NADP-Dihydrofinasteride, a Potent Bisubstrate Analog Inhibitor. http://pubs.acs.org/doi/pdf/10.1021/ja953069t

Leyden, J., Dunlap, F., & Miller, B., et el. (1999, June). Finasteride in the treatment of men with frontal male pattern hair loss.

Olsen, E. A., Hordinsky, M., & Whiting, D., et al. (2006, December). The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: Results of a randomized placebo-controlled study of dutasteride versus finasteride.

Schieck, Cynthia L.(1998, August) "Finasteride (Propecia ®)". http://www.chm.bris.ac.uk/motm/finasteride/Finasteride%20(Propecia)%20-%20Feature%20Molecule.htm

Personal tools